marketcaparena
Search

    FBIO

    Fortress Biotech, Inc.

    Company overview

    Market capitalization
    —
    Employees
    78
    Latest publication
    2026-09-29
    About Fortress Biotech, Inc.

    Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue18,718,000USD16,038,000USD16,079,000USD17,631,000USD16,413,000USD13,139,000USD15,120,000USD14,629,000USD
    Cost Of Revenue6,143,000USD7,344,000USD5,440,000USD5,755,000USD4,939,000USD4,790,000USD5,805,000USD5,285,000USD
    Gross Profit12,575,000USD8,694,000USD10,639,000USD11,876,000USD11,474,000USD8,349,000USD9,315,000USD9,344,000USD
    Research Development805,000USD540,000USD367,000USD208,000USD8,126,000USD3,938,000USD9,940,000USD9,446,000USD
    Selling General Administrative20,807,000USD15,893,000USD14,730,000USD17,415,000USD38,757,000USD25,663,000USD26,864,000USD21,993,000USD
    Total Operating Expenses22,581,000USD16,433,000USD15,428,000USD18,687,000USD47,947,000USD30,666,000USD36,660,000USD31,439,000USD
    Operating Income-10,006,000USD-7,739,000USD-4,789,000USD-6,811,000USD-36,473,000USD-22,317,000USD-27,345,000USD-22,095,000USD
    Total Other Income Expense Net10,928,000USD150,033,000USD-1,424,000USD15,664,000USD24,819,000USD-2,374,000USD1,366,000USD-4,530,000USD
    Interest Income1,581,000USD570,000USD637,000USD736,000USD622,000USD490,000USD526,000USD589,000USD
    Interest Expense1,476,000USD3,368,000USD1,709,000USD2,415,000USD2,074,000USD2,510,000USD2,594,000USD6,209,000USD
    Income Before Tax922,000USD142,294,000USD-6,213,000USD8,853,000USD-11,654,000USD-24,691,000USD-25,979,000USD-26,625,000USD
    Income Tax Expense320,000USD5,132,000USD-816,000USD26,000USD——336,000USD69,000USD
    Net Income602,000USD110,373,000USD-3,937,000USD5,850,000USD15,486,000USD-10,584,000USD-6,765,000USD-12,867,000USD
    Minority Interest1,070,000USD-26,789,000USD1,460,000USD-2,977,000USD27,140,000USD14,107,000USD19,550,000USD13,827,000USD
    Net Income Applicable To Common Shares-2,476,000USD———————
    Net Interest Income—-2,798,000USD-1,404,000USD-2,006,000USD-1,896,000USD-2,315,000USD-2,068,000USD-5,620,000USD
    Tax Provision—5,132,000USD-816,000USD26,000USD—0USD336,000USD69,000USD
    Net Income From Continuing Ops—137,162,000USD-5,397,000USD8,827,000USD-11,654,000USD-24,691,000USD-26,315,000USD-26,694,000USD
    Ebit—-7,739,000USD-4,504,000USD11,268,000USD-9,580,000USD-22,181,000USD-23,385,000USD-24,389,000USD
    Ebitda—-6,040,000USD-3,347,000USD12,425,000USD-8,424,000USD-20,990,000USD-21,780,000USD-21,066,000USD
    Depreciation And Amortization—1,699,000USD1,157,000USD1,157,000USD1,156,000USD1,191,000USD1,605,000USD3,323,000USD
    Reconciled Depreciation—1,219,000USD1,157,000USD1,157,000USD1,156,000USD1,191,000USD-1,241,000USD3,323,000USD
    Unclassified Operating Expenses———1,064,000USD1,064,000USD1,065,000USD——
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue63,262,000USD57,675,000USD84,513,000USD75,743,000USD68,791,000USD45,599,000USD36,629,000USD26,882,000USD
    Cost Of Revenue20,924,000USD20,879,000USD22,893,000USD30,775,000USD32,084,000USD14,594,000USD10,532,000USD6,125,000USD
    Gross Profit42,338,000USD36,796,000USD61,620,000USD44,968,000USD36,707,000USD31,005,000USD26,097,000USD20,757,000USD
    Research Development11,901,000USD56,881,000USD106,071,000USD134,876,000USD128,865,000USD64,109,000USD81,326,000USD87,383,000USD
    Selling General Administrative96,400,000USD87,731,000USD99,711,000USD113,656,000USD86,843,000USD61,166,000USD55,590,000USD53,371,000USD
    Unclassified Operating Expenses4,258,000USD2,563,000USD——9,540,000USD———
    Total Operating Expenses112,559,000USD147,175,000USD203,962,000USD248,532,000USD225,248,000USD125,275,000USD136,916,000USD140,754,000USD
    Operating Income-70,221,000USD-110,379,000USD-142,342,000USD-203,564,000USD-188,541,000USD-94,270,000USD-110,819,000USD-119,997,000USD
    Interest Income2,485,000USD2,683,000USD2,983,000USD1,398,000USD649,000USD1,518,000USD2,559,000USD1,104,000USD
    Interest Expense8,709,000USD9,927,000USD12,519,000USD13,642,000USD15,308,000USD15,326,000USD11,849,000USD10,340,000USD
    Net Interest Income-7,621,000USD-10,844,000USD-15,018,000USD-12,244,000USD-14,659,000USD-13,808,000USD-9,290,000USD-9,236,000USD
    Income Before Tax-33,535,000USD-120,543,000USD-153,633,000USD-213,464,000USD-164,353,000USD-102,849,000USD-101,660,000USD-130,800,000USD
    Income Tax Expense-620,000USD312,000USD521,000USD449,000USD473,000USD136,000USD-49,851,000USD-463,000USD
    Tax Provision-620,000USD312,000USD591,000USD449,000USD473,000USD136,000USD——
    Net Income6,815,000USD-45,997,000USD-60,637,000USD-86,575,000USD-64,703,000USD-46,526,000USD-39,960,000USD-84,147,000USD
    Net Income From Continuing Ops-32,915,000USD-120,855,000USD-182,615,000USD-213,913,000USD-164,826,000USD-102,985,000USD-101,660,000USD-130,800,000USD
    Ebit-24,826,000USD-108,955,000USD-141,718,000USD-203,047,000USD-152,959,000USD-93,145,000USD-93,132,000USD-120,460,000USD
    Ebitda-20,165,000USD-104,491,000USD-135,721,000USD-193,694,000USD-146,168,000USD-87,820,000USD-88,478,000USD-118,401,000USD
    Depreciation And Amortization4,661,000USD4,464,000USD5,997,000USD9,353,000USD6,791,000USD5,325,000USD4,654,000USD2,059,000USD
    Reconciled Depreciation4,661,000USD4,464,000USD8,958,000USD9,353,000USD6,791,000USD5,325,000USD4,654,000USD2,059,000USD
    Total Other Income Expense Net36,686,000USD-10,164,000USD-11,291,000USD-9,900,000USD24,188,000USD-8,579,000USD9,159,000USD-10,803,000USD
    Minority Interest39,730,000USD74,858,000USD104,309,000USD127,338,000USD-100,123,000USD96,661,000USD-61,700,000USD-57,789,000USD
    Non Operating Income Net Other————24,188,000USD-8,579,000USD9,159,000USD-10,803,000USD
    Net Income Applicable To Common Shares————-64,703,000USD-46,526,000USD-39,960,000USD-84,147,000USD
    Discontinued Operations———————-11,136,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets316,715,000USD356,874,000USD185,548,000USD181,407,000USD159,895,000USD178,071,000USD144,223,000USD127,085,000USD
    Cash And Equivalents196,576,000USD———————
    Total Current Assets245,506,000USD295,480,000USD123,841,000USD118,503,000USD110,396,000USD126,903,000USD90,371,000USD86,278,000USD
    Other Current Assets4,022,000USD4,839,000USD5,053,000USD2,342,000USD6,956,000USD4,734,000USD8,275,000USD4,966,000USD
    Other Non Current Assets1,259,000USD———————
    Total Liabilities110,629,000USD———————
    Total Current Liabilities62,018,000USD103,393,000USD49,744,000USD54,067,000USD57,521,000USD73,674,000USD71,399,000USD70,305,000USD
    Other Current Liabilities268,000USD———————
    Other Non Current Liabilities2,541,000USD———————
    Total Stockholder Equity164,140,000USD162,208,000USD49,873,000USD55,862,000USD43,924,000USD22,250,000USD22,737,000USD21,158,000USD
    Total Equity Including Noncontrolling Interest206,086,000USD———————
    Net Receivables36,246,000USD25,508,000USD29,941,000USD18,125,000USD16,202,000USD18,334,000USD10,402,000USD10,845,000USD
    Inventory8,156,000USD9,292,000USD9,624,000USD11,818,000USD12,852,000USD12,496,000USD14,431,000USD11,788,000USD
    Property Plant Equipment Net13,769,000USD14,248,000USD14,821,000USD14,932,000USD15,521,000USD16,099,000USD17,121,000USD17,555,000USD
    Accounts Payable11,856,000USD14,139,000USD14,238,000USD18,771,000USD20,190,000USD27,818,000USD31,636,000USD34,030,000USD
    Short Term Debt2,246,000USD4,721,000USD2,127,000USD7,754,000USD5,890,000USD4,034,000USD3,248,000USD3,764,000USD
    Common Stock33,000USD33,000USD32,000USD31,000USD30,000USD30,000USD28,000USD28,000USD
    Retained Earnings-624,147,000USD-623,679,000USD-734,052,000USD-730,115,000USD-735,965,000USD-751,451,000USD-740,867,000USD-734,102,000USD
    Intangible Assets—26,479,000USD27,605,000USD28,670,000USD29,734,000USD30,798,000USD31,863,000USD17,844,000USD
    Total Liab—154,500,000USD123,365,000USD116,222,000USD122,512,000USD145,585,000USD145,867,000USD139,823,000USD
    Other Current Liab—79,115,000USD33,023,000USD26,537,000USD30,457,000USD40,870,000USD35,583,000USD31,661,000USD
    Capital Stock—36,000USD34,000USD34,000USD33,000USD33,000USD31,000USD31,000USD
    Cash—255,841,000USD79,381,000USD86,218,000USD74,386,000USD91,339,000USD57,263,000USD58,853,000USD
    Cash And Short Term Investments—255,841,000USD79,381,000USD86,218,000USD74,386,000USD91,339,000USD57,263,000USD58,853,000USD
    Net Debt—-202,214,000USD-5,080,000USD-17,925,000USD-5,167,000USD-17,103,000USD18,697,000USD12,676,000USD
    Short Long Term Debt—2,500,000USD—5,625,000USD3,750,000USD1,875,000USD625,000USD1,250,000USD
    Short Long Term Debt Total—53,627,000USD74,301,000USD68,293,000USD69,219,000USD74,236,000USD75,960,000USD71,529,000USD
    Long Term Debt—36,878,000USD59,502,000USD47,774,000USD50,026,000USD56,382,000USD57,962,000USD52,473,000USD
    Long Term Investments—18,707,000USD17,660,000USD———2,585,000USD—
    Property Plant Equipment Gross—18,860,000USD19,965,000USD19,984,000USD20,480,000USD20,976,000USD29,229,000USD29,520,000USD
    Common Stock Shares Outstanding—38,412,716shares279,018,890shares33,100,961shares29,824,182shares26,450,218shares20,240,645shares19,697,290shares
    Non Current Assets Total—61,394,000USD61,707,000USD62,904,000USD49,499,000USD51,168,000USD53,852,000USD40,807,000USD
    Non Current Liabilities Total—51,107,000USD73,621,000USD62,155,000USD64,991,000USD71,911,000USD74,468,000USD69,518,000USD
    Non Current Liabilities Other—2,201,000USD1,447,000USD1,616,000USD1,662,000USD1,709,000USD1,756,000USD1,753,000USD
    Non Currrent Assets Other—740,000USD1,621,000USD19,302,000USD3,024,000USD4,271,000USD3,316,000USD3,345,000USD
    Net Working Capital—192,087,000USD74,097,000USD64,436,000USD52,875,000USD53,229,000USD18,972,000USD15,973,000USD
    Unclassified Non Current Assets—1,220,000USD——1,220,000USD—-1,033,000USD2,063,000USD
    Unclassified Current Liabilities—2,918,000USD—-4,620,000USD-2,766,000USD———
    Unclassified Non Current Liabilities—12,028,000USD12,672,000USD12,765,000USD13,303,000USD13,820,000USD14,750,000USD15,292,000USD
    Unclassified Equity—785,818,000USD783,859,000USD785,912,000USD779,826,000USD773,638,000USD763,545,000USD755,201,000USD
    Current Deferred Revenue———————-1,601,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets185,548,000USD144,223,000USD167,526,000USD294,301,000USD396,503,000USD333,413,000USD226,422,000USD140,993,000USD
    Intangible Assets27,605,000USD31,863,000USD20,287,000USD27,197,000USD12,552,000USD14,629,000USD7,377,000USD1,417,000USD
    Other Current Assets5,053,000USD8,275,000USD10,500,000USD9,661,000USD7,066,000USD6,722,999USD4,133,000USD21,919,000USD
    Total Liab123,365,000USD145,867,000USD165,939,000USD244,276,000USD170,626,000USD136,414,000USD153,890,000USD121,250,000USD
    Total Stockholder Equity49,873,000USD22,737,000USD22,544,000USD41,721,000USD108,674,000USD100,338,000USD26,215,000USD1,852,000USD
    Other Current Liab33,023,000USD35,583,000USD39,801,000USD56,391,000USD43,231,000USD33,841,000USD26,560,000USD18,680,000USD
    Common Stock32,000USD28,000USD15,000USD110,000USD101,000USD95,000USD574,000USD717,000USD
    Capital Stock34,000USD31,000USD18,000USD113,000USD104,000USD98,000USD575,000USD718,000USD
    Retained Earnings-734,052,000USD-740,867,000USD-694,870,000USD-634,233,000USD-547,463,000USD-482,760,000USD-436,234,000USD-396,274,000USD
    Cash79,381,000USD57,263,000USD80,927,000USD178,266,000USD305,744,000USD233,351,000USD136,858,000USD65,508,000USD
    Cash And Short Term Investments79,381,000USD57,263,000USD80,927,000USD178,266,000USD305,744,000USD233,351,000USD136,858,000USD83,112,000USD
    Total Current Assets123,841,000USD90,371,000USD117,022,000USD230,432,000USD346,462,000USD266,149,999USD156,252,000USD111,207,000USD
    Total Current Liabilities49,744,000USD71,399,000USD84,908,000USD127,715,000USD101,042,000USD51,760,000USD45,616,000USD55,614,000USD
    Net Debt-5,080,000USD18,697,000USD7,665,000USD-50,922,000USD-230,767,000USD-144,275,000USD-21,716,000USD13,995,000USD
    Short Term Debt2,127,000USD3,248,000USD9,454,000USD12,630,000USD7,426,000USD6,371,000USD9,004,000USD19,078,000USD
    Short Long Term Debt Total74,301,000USD75,960,000USD88,592,000USD127,344,000USD74,977,000USD89,076,000USD115,142,000USD79,503,000USD
    Long Term Debt59,502,000USD57,962,000USD60,856,000USD93,142,000USD46,564,000USD59,036,000USD82,426,000USD60,425,000USD
    Long Term Investments17,660,000USD2,585,000USD——0USD17,566,000USD11,148,000USD0USD
    Net Receivables29,941,000USD10,402,000USD15,389,000USD28,346,000USD23,790,000USD24,672,000USD14,404,000USD5,498,000USD
    Inventory9,624,000USD14,431,000USD10,206,000USD14,159,000USD9,862,000USD1,404,000USD857,000USD678,000USD
    Accounts Payable14,238,000USD31,636,000USD34,810,000USD57,244,000USD47,429,000USD11,412,000USD10,052,000USD17,856,000USD
    Property Plant Equipment Net14,821,000USD17,121,000USD23,495,000USD33,011,000USD34,071,000USD32,409,999USD33,913,000USD12,019,000USD
    Property Plant Equipment Gross19,965,000USD29,229,000USD32,387,000USD33,011,000USD15,066,000USD32,410,000USD33,913,000USD12,019,000USD
    Common Stock Shares Outstanding279,018,890shares20,784,000shares8,111,000shares5,925,000shares5,447,000shares4,800,000shares3,647,000shares2,897,000shares
    Non Current Assets Total61,707,000USD53,852,000USD50,504,000USD63,869,000USD50,041,000USD67,263,000USD70,170,000USD29,786,000USD
    Non Current Liabilities Total73,621,000USD74,468,000USD81,030,999USD116,561,000USD69,584,000USD84,654,000USD108,274,000USD65,636,000USD
    Non Current Liabilities Other1,447,000USD1,756,000USD1,893,000USD1,847,000USD2,033,000USD———
    Non Currrent Assets Other1,621,000USD3,316,000USD4,284,000USD3,661,000USD3,418,000USD1,013,000USD17,732,000USD16,350,000USD
    Net Working Capital74,097,000USD18,972,000USD32,114,000USD102,717,000USD245,420,000USD213,612,000USD110,636,000USD55,593,000USD
    Unclassified Non Current Liabilities12,672,000USD14,750,000USD18,281,999USD21,572,000USD18,954,000USD23,669,000USD23,712,000USD—
    Unclassified Equity783,859,000USD763,545,000USD717,384,000USD675,731,000USD655,932,000USD589,671,000USD460,800,000USD399,255,000USD
    Short Long Term Debt—625,000USD3,000,000USD10,183,000USD5,322,000USD5,300,000USD7,220,000USD19,078,000USD
    Unclassified Non Current Assets—-1,033,000USD2,438,000USD—-3,418,000USD-1,012,999USD-17,732,000USD-16,350,000USD
    Current Deferred Revenue——843,000USD728,000USD2,611,000USD—1,134,000USD1,329,000USD
    Accumulated Other Comprehensive Income——-3,000USD——-6,766,000USD500,000USD-2,564,000USD
    Unclassified Current Liabilities——-3,000,000USD-9,461,000USD-4,977,000USD-5,164,000USD-8,354,000USD-20,407,000USD
    Other Liab————2,033,000USD1,949,000USD2,136,000USD5,211,000USD
    Other Assets————3,418,000USD2,658,000USD17,732,000USD16,350,000USD
    Net Tangible Assets————96,119,000USD85,706,000USD26,214,000USD1,851,000USD
    Short Term Investments—————17,566,000USD15,000,000USD17,604,000USD
    Unclassified Current Assets—————-17,566,000USD-15,000,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation2,282,000USD
    Stock Based Compensation4,634,000USD
    Change To Account Receivables-6,482,000USD
    Change To Inventory1,468,000USD
    Change To Liabilities3,536,000USD
    Change In Working Capital3,583,000USD
    Operating Cash Flow144,574,000USD
    Capital Expenditures-79,000USD
    Investing Cash Flow-79,000USD
    Financing Cash Flow-27,300,000USD
    Change In Cash117,195,000USD
    End Cash Flow197,796,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income110,373,000USD-5,397,000USD8,827,000USD-11,654,000USD-24,691,000USD-26,315,000USD-26,694,000USD-10,948,000USD
    Depreciation1,699,000USD1,157,000USD1,157,000USD1,156,000USD1,676,000USD-1,241,000USD3,323,000USD1,191,000USD
    Stock Based Compensation1,756,000USD2,459,000USD3,198,000USD16,793,000USD6,289,000USD16,190,000USD6,573,000USD4,999,000USD
    Other Non Cash Items35,991,000USD42,000USD-14,759,000USD-27,077,000USD143,000USD4,192,000USD2,315,000USD-13,888,000USD
    Change To Account Receivables4,403,000USD-11,775,000USD-1,999,000USD2,573,000USD-8,127,000USD750,000USD-827,000USD-712,000USD
    Change To Inventory332,000USD2,194,000USD1,034,000USD-356,000USD1,935,000USD-2,643,000USD-2,101,000USD893,000USD
    Change In Working Capital55,788,000USD-10,805,000USD-4,533,000USD-6,778,000USD-2,980,000USD-5,733,000USD-5,576,000USD-3,192,000USD
    Total Cash From Operating Activities203,851,000USD-12,544,000USD-6,110,000USD-27,560,000USD-19,563,000USD-12,907,000USD-20,059,000USD-21,838,000USD
    Capital Expenditures0USD0USD0USD0USD0USD0USD0USD0USD
    Free Cash Flow203,851,000USD-12,544,000USD-6,110,000USD-27,560,000USD-19,563,000USD-12,907,000USD-20,059,000USD-21,838,000USD
    Net Borrowings-14,494,000USD0USD-704,000USD-4,932,000USD0USD5,002,000USD-17,332,000USD—
    Total Cash From Financing Activities-27,391,000USD5,707,000USD15,072,000USD4,521,000USD52,142,000USD25,806,000USD2,711,000USD14,265,000USD
    Dividends Paid0USD-166,000USD-166,000USD-166,000USD-166,000USD-166,000USD-176,000USD-2,184,000USD
    Sale Purchase Of Stock-14,335,000USD0USD0USD-115,000USD-150,000USD—0USD-2,615,000USD
    Issuance Of Capital Stock0USD5,461,000USD14,138,000USD9,115,000USD52,967,000USD21,187,000USD20,379,000USD15,995,000USD
    Change In Cash176,460,000USD-6,837,000USD11,832,000USD-16,953,000USD33,744,000USD-2,101,000USD-17,348,000USD-7,573,000USD
    Begin Period Cash Flow80,601,000USD87,438,000USD75,606,000USD92,559,000USD58,815,000USD60,916,000USD78,264,000USD85,837,000USD
    End Period Cash Flow257,061,000USD80,601,000USD87,438,000USD75,606,000USD92,559,000USD58,815,000USD60,916,000USD78,264,000USD
    Other Cashflows From Financing Activities-27,391,000USD10,560,000USD1,804,000USD504,000USD-34,000USD-217,000USD-501,000USD-4,205,000USD
    Unclassified Financing Cash Flow28,829,000USD-4,687,000USD14,138,000USD9,230,000USD52,492,000USD—20,720,000USD23,269,000USD
    Total Cashflows From Investing Activities—7,251,000USD2,870,000USD6,086,000USD1,165,000USD-15,000,000USD——
    Other Cashflows From Investing Activities—7,251,000USD-7,251,000USD6,086,000USD1,165,000USD-15,000,000USD——
    Investments——2,870,000USD6,086,000USD1,165,000USD-15,000,000USD0USD0USD
    Unclassified Investing Cash Flow——7,251,000USD-6,086,000USD-1,165,000USD15,000,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-32,915,000USD-120,855,000USD-154,154,000USD-213,913,000USD-164,826,000USD-102,985,000USD-101,660,000USD-130,800,000USD
    Depreciation4,661,000USD4,464,000USD5,997,000USD9,353,000USD6,791,000USD5,325,000USD4,654,000USD2,059,000USD
    Stock Based Compensation28,739,000USD32,619,000USD17,029,000USD22,987,000USD19,486,000USD13,451,000USD13,188,000USD15,012,000USD
    Other Non Cash Items-41,166,000USD11,708,000USD15,422,000USD2,887,000USD24,435,000USD10,488,000USD12,047,000USD8,858,000USD
    Change To Account Receivables-19,328,000USD4,471,000USD12,522,000USD-5,380,000USD768,000USD-5,859,000USD-8,141,000USD2,260,000USD
    Change To Inventory4,807,000USD-4,225,000USD3,953,000USD1,744,000USD-8,458,000USD-547,000USD-179,000USD-507,000USD
    Change In Working Capital-25,096,000USD-8,127,000USD-12,519,000USD-715,000USD36,373,000USD-4,781,000USD-4,841,000USD5,736,000USD
    Total Cash From Operating Activities-65,777,000USD-80,191,000USD-128,225,000USD-179,401,000USD-116,540,000USD-83,682,000USD-94,961,000USD-98,848,000USD
    Capital Expenditures0USD-15,000,000USD-8,098,000USD-3,055,000USD-16,346,000USD-7,164,000USD-9,395,000USD-9,356,000USD
    Free Cash Flow-65,777,000USD-95,191,000USD-136,323,000USD-182,456,000USD-132,886,000USD-90,846,000USD-104,356,000USD-108,204,000USD
    Total Cashflows From Investing Activities10,121,000USD-15,000,000USD-2,103,000USD-22,928,000USD40,514,000USD-7,164,000USD20,097,000USD18,824,000USD
    Net Borrowings-5,636,000USD-7,330,000USD-38,794,000USD49,248,000USD-15,033,000USD-29,671,000USD14,748,000USD1,000USD
    Total Cash From Financing Activities77,442,000USD70,641,000USD32,739,000USD75,319,000USD148,994,000USD172,410,000USD146,714,000USD50,648,000USD
    Dividends Paid-664,000USD-4,710,000USD-8,768,000USD-8,780,000USD-8,780,000USD-6,752,000USD-2,559,000USD-2,344,000USD
    Sale Purchase Of Stock-265,000USD0USD-400,000USD-1,196,000USD24,280,000USD-70,000USD-24,000USD-234,000USD
    Issuance Of Capital Stock81,681,000USD82,844,000USD70,971,000USD42,965,000USD172,226,000USD224,883,000USD144,236,000USD38,420,000USD
    Change In Cash21,786,000USD-24,550,000USD-97,589,000USD-127,010,000USD72,968,000USD81,564,000USD71,850,000USD-29,376,000USD
    Begin Period Cash Flow58,815,000USD83,365,000USD180,954,000USD307,964,000USD234,996,000USD153,432,000USD81,582,000USD110,958,000USD
    End Period Cash Flow80,601,000USD58,815,000USD83,365,000USD180,954,000USD307,964,000USD234,996,000USD153,432,000USD81,582,000USD
    Other Cashflows From Investing Activities1,165,000USD—-2,040,000USD127,000USD-11,780,000USD-5,238,000USD4,838,000USD7,508,000USD
    Other Cashflows From Financing Activities-625,000USD-163,000USD-75,000USD47,727,000USD-5,401,000USD90,842,000USD33,662,000USD-2,573,000USD
    Unclassified Investing Cash Flow8,956,000USD15,000,000USD10,466,000USD2,928,000USD11,780,000USD12,402,000USD7,050,000USD-31,932,000USD
    Unclassified Financing Cash Flow84,632,000USD82,844,000USD80,776,000USD-11,680,000USD153,928,000USD118,061,000USD100,887,000USD55,798,000USD
    Investments—-15,000,000USD-2,431,000USD-22,928,000USD56,860,000USD-7,164,000USD17,604,000USD52,604,000USD
    Change To Liabilities————46,347,000USD6,522,000USD2,698,000USD4,686,000USD
    Cash And Cash Equivalents Changes————72,968,000USD81,564,000USD71,850,000USD-29,376,000USD
    Unclassified Operating Cash Flow————-38,799,000USD-5,180,000USD-18,349,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductAccutane3,314,000USD0001104659-26-061233
    Q1 2026Quarterly · 2026-03-31ProductEmrosi6,252,000USD0001104659-26-061233
    Q1 2026Quarterly · 2026-03-31ProductFoam Franchise Products1,050,000USD0001104659-26-061233
    Q1 2026Quarterly · 2026-03-31ProductOther Legacy Product Revenue277,000USD0001104659-26-061233
    Q1 2026Quarterly · 2026-03-31ProductQbrexza5,028,000USD0001104659-26-061233
    Q1 2026Quarterly · 2026-03-31ProductRoyalty77,000USD0001104659-26-061233
    Q1 2026Quarterly · 2026-03-31SegmentFortress Biotech Inc77,000USD0001104659-26-061233
    Q1 2026Quarterly · 2026-03-31SegmentJourney15,961,000USD0001104659-26-061233
    FY 2025Yearly · 2025-12-31ProductAccutane12,882,000USD0001104659-26-037874
    FY 2025Yearly · 2025-12-31ProductEmrosi14,745,000USD0001104659-26-037874
    FY 2025Yearly · 2025-12-31ProductFoam Franchise Products5,859,000USD0001104659-26-037874
    FY 2025Yearly · 2025-12-31ProductOther Legacy Product Revenue2,739,000USD0001104659-26-037874
    FY 2025Yearly · 2025-12-31ProductQbrexza25,014,000USD0001104659-26-037874
    FY 2025Yearly · 2025-12-31ProductRoyalty0USD0001104659-26-037874
    FY 2025Yearly · 2025-12-31SegmentAvenue Therapeutics Inc1,404,000USD0001104659-26-037874
    FY 2025Yearly · 2025-12-31SegmentJourney61,858,000USD0001104659-26-037874
    Q3 2025Quarterly · 2025-09-30ProductAccutane2,769,000USD0001104659-25-111989
    Q3 2025Quarterly · 2025-09-30ProductEmrosi4,883,000USD0001104659-25-111989
    Q3 2025Quarterly · 2025-09-30ProductOther Legacy Product Revenue701,000USD0001104659-25-111989
    Q3 2025Quarterly · 2025-09-30ProductQbrexza7,361,000USD0001104659-25-111989
    Q3 2025Quarterly · 2025-09-30ProductRoyalty0USD0001104659-25-111989
    Q3 2025Quarterly · 2025-09-30ProductVyne Acquisition Products Amzeeq And Zilxi1,311,000USD0001104659-25-111989
    Q2 2025Quarterly · 2025-06-30ProductAccutane3,395,000USD0001558370-25-011570
    Q2 2025Quarterly · 2025-06-30ProductAmzeeq879,000USD0001558370-25-011570
    Q2 2025Quarterly · 2025-06-30ProductEmrosi2,795,000USD0001558370-25-011570
    Q2 2025Quarterly · 2025-06-30ProductOther Legacy Product Revenue735,000USD0001558370-25-011570
    Q2 2025Quarterly · 2025-06-30ProductQbrexza6,949,000USD0001558370-25-011570
    Q2 2025Quarterly · 2025-06-30ProductZilxi256,000USD0001558370-25-011570
    Q2 2025Quarterly · 2025-06-30SegmentAvenue Therapeutics Inc1,404,000USD0001558370-25-011570
    Q2 2025Quarterly · 2025-06-30SegmentJourney15,009,000USD0001558370-25-011570
    Q1 2025Quarterly · 2025-03-31ProductAccutane3,655,000USD0001558370-25-007898
    Q1 2025Quarterly · 2025-03-31ProductAmzeeq1,100,000USD0001558370-25-007898
    Q1 2025Quarterly · 2025-03-31ProductEmrosi2,070,000USD0001558370-25-007898
    Q1 2025Quarterly · 2025-03-31ProductOther Legacy Product Revenue727,000USD0001558370-25-007898
    Q1 2025Quarterly · 2025-03-31ProductQbrexza5,161,000USD0001558370-25-007898
    Q1 2025Quarterly · 2025-03-31ProductZilxi426,000USD0001558370-25-007898
    FY 2024Yearly · 2024-12-31ProductAccutane19,407,000USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31ProductCollaborationrevenue1,500,000USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31ProductEmrosi0USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31ProductFoam Franchise Products6,652,000USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31ProductOther Legacy Product Revenue5,002,000USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31ProductQbrexza25,114,000USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31SegmentCheckpoint41,000USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31SegmentFortress Biotech Inc1,500,000USD0001104659-26-037874
    FY 2024Yearly · 2024-12-31SegmentJourney56,134,000USD0001104659-26-037874
    Q3 2024Quarterly · 2024-09-30ProductAccutane3,996,000USD0001558370-24-015740
    Q3 2024Quarterly · 2024-09-30ProductAmzeeq1,542,000USD0001558370-24-015740
    Q3 2024Quarterly · 2024-09-30ProductOther Legacy Product Revenue950,000USD0001558370-24-015740
    Q3 2024Quarterly · 2024-09-30ProductQbrexza7,583,000USD0001558370-24-015740
    Q3 2024Quarterly · 2024-09-30ProductZilxi558,000USD0001558370-24-015740
    Q2 2024Quarterly · 2024-06-30ProductAccutane5,719,000USD0001558370-25-011570
    Q2 2024Quarterly · 2024-06-30ProductAmzeeq1,205,000USD0001558370-25-011570
    Q2 2024Quarterly · 2024-06-30ProductOther Legacy Product Revenue726,000USD0001558370-25-011570
    Q2 2024Quarterly · 2024-06-30ProductQbrexza6,836,000USD0001558370-25-011570
    Q2 2024Quarterly · 2024-06-30ProductZilxi369,000USD0001558370-25-011570
    Q2 2024Quarterly · 2024-06-30SegmentCheckpoint41,000USD0001558370-25-011570
    Q2 2024Quarterly · 2024-06-30SegmentJourney14,855,000USD0001558370-25-011570
    Q1 2024Quarterly · 2024-03-31ProductAccutane5,819,000USD0001558370-25-007898
    Q1 2024Quarterly · 2024-03-31ProductAmzeeq755,000USD0001558370-25-007898
    Q1 2024Quarterly · 2024-03-31ProductOther Legacy Product Revenue1,166,000USD0001558370-25-007898
    Q1 2024Quarterly · 2024-03-31ProductQbrexza5,017,000USD0001558370-25-007898
    Q1 2024Quarterly · 2024-03-31ProductZilxi273,000USD0001558370-25-007898
    Q4 2023Quarterly · 2023-12-31SegmentDermatology Products Sales15,257,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31SegmentPharmaceutical And Biotechnology Product Development4,689,000USDLegacy provider
    FY 2023Yearly · 2023-12-31ProductAccutane20,168,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31ProductAmzeeq6,201,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31ProductCollaborationrevenue5,229,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31ProductOther Legacy Product Revenue25,543,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31ProductQbrexza25,410,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31ProductZilxi1,962,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31SegmentCheckpoint103,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31SegmentFortress Biotech Inc5,229,000USD0001558370-25-004160
    FY 2023Yearly · 2023-12-31SegmentJourney79,181,000USD0001558370-25-004160
    Q3 2023Quarterly · 2023-09-30SegmentDermatology Products Sales34,539,000USD0001558370-24-015740
    Q3 2023Quarterly · 2023-09-30SegmentPharmaceutical And Biotechnology Product Development213,000USD0001558370-24-015740
    Q2 2023Quarterly · 2023-06-30ProductAccutane5,579,000USD0001558370-23-014854
    Q2 2023Quarterly · 2023-06-30ProductAmzeeq1,374,000USD0001558370-23-014854
    Q2 2023Quarterly · 2023-06-30ProductExelderm538,000USD0001558370-23-014854
    Q2 2023Quarterly · 2023-06-30ProductQbrexza8,079,000USD0001558370-23-014854
    Q2 2023Quarterly · 2023-06-30ProductTargadox664,000USD0001558370-23-014854
    Q2 2023Quarterly · 2023-06-30ProductXimino155,000USD0001558370-23-014854
    Q2 2023Quarterly · 2023-06-30ProductZilxi572,000USD0001558370-23-014854
    Q2 2023Quarterly · 2023-06-30SegmentDermatology Products Sales17,172,000USD0001558370-24-012063
    Q2 2023Quarterly · 2023-06-30SegmentPharmaceutical And Biotechnology Product Development214,000USD0001558370-24-012063
    Q1 2023Quarterly · 2023-03-31SegmentDermatology Products Sales12,213,000USD0001558370-24-008299
    Q1 2023Quarterly · 2023-03-31SegmentPharmaceutical And Biotechnology Product Development216,000USD0001558370-24-008299
    Q4 2022Quarterly · 2022-12-31SegmentDermatology Products Sales15,966,000USDLegacy provider
    Q4 2022Quarterly · 2022-12-31SegmentPharmaceutical And Biotechnology Product Development438,000USDLegacy provider
    FY 2022Yearly · 2022-12-31ProductAccutane18,373,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31ProductAmzeeq7,242,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31ProductExelderm3,463,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31ProductLuxamend0USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31ProductQbrexza26,715,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31ProductTargadox7,972,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31ProductXimino4,957,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31ProductZilxi2,273,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31SegmentDermatology Products Sales73,669,000USD0001558370-24-004272
    FY 2022Yearly · 2022-12-31SegmentPharmaceutical And Biotechnology Product Development2,074,000USD0001558370-24-004272
    FY 2021Yearly · 2021-12-31ProductAccutane10,053,000USD0001558370-23-005282
    FY 2021Yearly · 2021-12-31ProductAmzeeq0USD0001558370-23-005282

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.